A phase 3 study of Enasidenib (ENA) versus conventional care regimens (CCR) in older patients with late-stage mutant-IDH2 (MIDH2) relapsed/refractory acute myeloid leukemia (R/R AM... by Papayannidis, C, DiNardo, C, Montesinos, P, Schuh, A, Vyas, P, Wei, A, Ommen, H, Semochkin, S, Kim, H, Larson, R, Koprivnikar, J, Frankfurt, O, Thol, F, Chromik, J, Byrne, J, Pigneux, A, Thomas, X, Salamero, O, Vidriales, M, Doronin, V, Dohner, H, Fathi, A, Laille, E, Yu, X, Hasan, M, Martin-Regueira, P, de Botton, S

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial by de Botton, S, Montesinos, P, Schuh, AC, Papayannidis, C, Vyas, P, Wei, AH, Ommen, H, Semochkin, S, Kim, H-J, Larson, RA, Koprivnikar, J, Frankfurt, O, Thol, F, Chromik, J, Byrne, J, Pigneux, A, Thomas, X, Salamero, O, Vidriales, MB, Doronin, V, Döhner, H, Fathi, AT, Laille, E, Yu, X, Hasan, M, Martin-Regueira, P, DiNardo, CD

Phase III, randomized, placebo-controlled trial of CC-486 (Oral Azacitidine) in patients with lower-risk myelodysplastic syndromes by Garcia-Manero, G, Santini, V, Almeida, A, Platzbecker, U, Jonasova, A, Silverman, LR, Falantes, J, Reda, G, Buccisano, F, Fenaux, P, Buckstein, R, Diez Campelo, M, Larsen, S, Valcarcel, D, Vyas, P, Giai, V, Olíva, EN, Shortt, J, Niederwieser, D, Mittelman, M, Fianchi, L, La Torre, I, Zhong, J, Laille, E, Lopes de Menezes, D, Skikne, B, Beach, CL, Giagounidis, A